Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Locks Onto $18.5M in Additional Private Equity

SAN FRANCISCO, Dec. 26 - Structural genomics company Syrrx said on Wednesday it received $18.5 million in its latest round of private equity funding.

 

The investment, led by Zurich, Switzerland-based HBM Partners, brings to $98.5 million Syrxx's total equity-investment pot, according to the company.

 

"Along with the $20 million debt financing arranged for our new facility earlier this year, this round of financing will assure investors that our operating funds will allow for the completion of our strategic plan through 2004," Norman Halleen, CFO of Syrrx, said in a statement.

 

Two weeks ago, Syrrx, based in San Diego, announced a research collaboration with Celera Genomics  under which Syrrx will receive a series of R&D payments to determine the three-dimensional structures of proteins identified by Celera as potential drug targets.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more